Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Indivior ( (GB:INDV) ).
Indivior PLC has appointed Daniel A. Ninivaggi as an Independent Non-Executive Director to its Board, effective January 31, 2025. Ninivaggi brings extensive public company experience and expertise in operations, capital allocation, and legal and finance, which is expected to enhance Indivior’s mission to transform the lives of patients struggling with opioid use disorder. This strategic leadership change is anticipated to strengthen Indivior’s position as a global leader in OUD treatments, benefiting stakeholders and supporting the company’s continued growth.
More about Indivior
Indivior is a global pharmaceutical company focused on developing medicines for substance use disorders (SUD), with a vision to provide evidence-based treatment for chronic conditions and co-occurring disorders of SUD worldwide. Headquartered in Richmond, VA, Indivior has a strong portfolio of opioid use disorder (OUD) treatments and a pipeline of product candidates to expand its reach, with its products available in over 30 countries.
YTD Price Performance: -6.49%
Average Trading Volume: 278,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.19B
See more data about INDV stock on TipRanks’ Stock Analysis page.
